Pilot Study of Bone Mineral Density in Breast Cancer Patients Treated with Adjuvant Chemotherapy

References

• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1–15, 71–85
   PubMed Web of Science ®Google Scholar
• Consensus Conference on Adjuvant Chemotherapy for Breast Cancer. JAMA 1985; 254: 3461–3463
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes ten-year results. JAMA 1995; 273: 542–547
   PubMed Web of Science ®Google Scholar
• Khanuja P S, Gimotty P, Fregene T, George J, Pienta K J. Angiogenesis quantification as a prognostic factor for primary breast carcinoma 2 cms or less. Adj Ther Cancer 1993; 7: 220–226
   Google Scholar
• Wood W C, Budman D R, Korzun A H, Cooper M R, Younger J, Hart R D, Moore A, Ellerton J A, Norton L, Ferree C R, Ballow A C, Frei E, Henderson I C. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–1266
   PubMed Web of Science ®Google Scholar
• Soborinko L G, Levine R A, DeConti R C. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agent. Am J Obstet Gynecol 1971; 109: 135–139
   PubMed Web of Science ®Google Scholar
• Miller J J, Williams G F, Lessing J C. Multiple late complications of therapy with cyclophosphamide including ovarian dysfunction. Am J Med 1971; 50: 530–535
   PubMed Web of Science ®Google Scholar
• Women G L, Tailey K F, Hobbs J B, et al. Cyclophosphamide induced ovarian failure. N Engl J Med 1973; 289: 1159–1162
   PubMed Web of Science ®Google Scholar
• Kayuama H, Wada T, Nishizawa L. Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39: 1403–1409
   PubMed Web of Science ®Google Scholar
• Samaan N A, DeAsis D N, Buzdar A U, et al. Pituitary ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer 1978; 41: 2084–2087
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Buzdar A U, Marcus C E, et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; 1: 105–109
   PubMedGoogle Scholar
• Dristan A M, Swbortz M K, Fracchia A A, et al. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 1983; 51: 803–807
   PubMed Web of Science ®Google Scholar
• Fisher B, Sherman B, Rockette H, et al. L-Phenylalanine mustard in the management of premenopausal patients with primary breast cancer. Cancer 1979; 44: 847–857
   PubMed Web of Science ®Google Scholar
• Schilsky R L, Lewis B J, Sheries R J, et al. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 1980; 93: 109–114
   PubMed Web of Science ®Google Scholar
• Ratcliffe M A, Laanham S A, Reid D M, et al. Bone mineral density in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol 1992; 10: 181–187
   PubMed Web of Science ®Google Scholar
• Redman J, Bajoruias R. D, Wang R. G. Bone mineralization in women following successful treatment in Hodgkin's disease. Am J Med 1988; 85: 65–71
   PubMed Web of Science ®Google Scholar
• Love R R, Mozess R B, Tormey D C. Bone mineral density (BMD) in women with breast cancer treated with tamoxifen for two years. Breast Cancer Res Treat 1987; 10: 112
   Web of Science ®Google Scholar
• Forander T, Rutquist L E, Sjoberg H E, et al. Long-term adjuvant tamoxifen in early breast cancer: a effective bone mineral density in postmenopausal women. J Clin Oncol 1990; 8: 1019–1024
   PubMed Web of Science ®Google Scholar
• Love R R, Mazess R B, Barden H S, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852–856
   PubMed Web of Science ®Google Scholar
• Bruning P F, Pit M J, De Jong-Bakker M, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990; 61: 302–310
   Google Scholar
• Trotter M, Broman G E, Peterson R R. Densities of bones of white and negro skeletons. J Bone Joint Surg 1960; 42: 50–58
   PubMed Web of Science ®Google Scholar
• Farmer M E, White L R, Brody J A, et al. Race and sex differences in hip fracture incidence. Am J Public Health 1984; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Statistical Package for the Social Sciences. PC Version 6.0.1., SPSS Inc., Chicago, IL 1993
   Google Scholar
• Aloia J F, Vaswani A, Yeh J K, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120: 97–103
   PubMed Web of Science ®Google Scholar
• Garnett T, Studd J, Watson N, et al. A cross-sectional study of the effects of long-term percutaneous hormone replacement therapy on bone density. Obstet Gynecol 1991; 78: 1002–1007
   PubMed Web of Science ®Google Scholar
• Holland E FN, Leather A T, Studd J WW. The effect of 25 mg percutaneous estradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994; 83: 43–6
   PubMed Web of Science ®Google Scholar
• Slosman D O, Rizzoli R, Buchs B, et al. Comparative study of the performances of x-ray and gadolinium 153 bone densitometers at the level of the spine, femoral neck, and femoral shaft. Eur J Nucl Med 1990; 17: 3–9
   PubMedGoogle Scholar
• Kelley T L, Slovik D M, Schoenfeld D A, et al. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. J Clin Endocrinol Metab 1988; 67: 839–844
   PubMed Web of Science ®Google Scholar
• Di Renzo G C, Coata G, Cosmi E V, et al. Management of postmenopausal osteoporosis. Eur J Obstet Gynecol Reprod Biol 1994; 56: 147–53
   PubMedGoogle Scholar
• Chestnut C H, McClung M R, Ensurd K E, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages in bone mass and bone remodeling. Am J Med 1995; 99(2)144–52
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures-1996. American Cancer Society, New York 1996
   Google Scholar
• Blot W J, Devisa S S, Fraumeni J F. Declining breast cancer mortality among young American women. J Natl Cancer Inst 1987; 78: 451–154
   PubMed Web of Science ®Google Scholar
• Valagussa P, Moliterni A, Zambett M, et al. Long-term sequelae from adjuvant chemistry. Recent Results Cancer Res 1993; 127: 247–255
   PubMedGoogle Scholar
• Fisher B, Redmond C, Dimitrov N, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473–178
   PubMed Web of Science ®Google Scholar
• Mansour E G, Gray R, Shatila A H, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An inter-group study. N Engl J Med 1989; 320: 485–90
   PubMed Web of Science ®Google Scholar